Shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) rose 3.2% during mid-day trading on Monday . The company traded as high as $7.13 and last traded at $7.09, with a volume of 104,380 shares traded. The stock had previously closed at $6.87.

FOMX has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Guggenheim reiterated a “buy” rating and set a $10.00 price target on shares of Foamix Pharmaceuticals in a research note on Tuesday, May 10th.

The firm’s market cap is $217.05 million. The stock has a 50 day moving average price of $6.54 and a 200 day moving average price of $6.55.

Foamix Pharmaceuticals (NASDAQ:FOMX) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.08. Equities research analysts anticipate that Foamix Pharmaceuticals Ltd. will post ($0.89) EPS for the current fiscal year.

An institutional investor recently raised its position in Foamix Pharmaceuticals stock. J. Goldman & Co LP increased its position in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 22.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 580,000 shares of the specialty pharmaceutical company’s stock after buying an additional 105,190 shares during the period. J. Goldman & Co LP owned 1.90% of Foamix Pharmaceuticals worth $4,704,000 as of its most recent filing with the SEC.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.